Introduction {#S1}
============

Chronic kidney disease (CKD) accounts for 10% to 15% population worldwide, which is associated with high annual rates of mortality and cardiovascular complications ([@B48]). Identifying potentially modifiable risk factors for CKD is critical in order to devise effective, population-based preventive strategies.

A salt restriction \<90 mmol per day (equivalent to 5 g per day of salt or 2 g per day of sodium) is recommended in the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline ([@B21]). The Working Group graded this recommendation as "1C," indicating that controlling salt intake can be evaluated as a candidate for developing a policy or a performance measure (Grade level 1), but from low quality of evidence (Grade C). This recommendation was mainly based on expert opinion and extrapolation from previous studies between sodium intake and blood pressure. Observational epidemiology studies have indicated that sodium intake was positively associated with blood pressure and proteinuria, which are strong predictors of CKD progression and cardiovascular diseases (CVDs) ([@B17]). In addition, existing clinical trials in sodium restriction showed significant reductions in blood pressures and proteinuria ([@B46]; [@B42]; [@B39]; [@B15]; [@B10]). However, prospective cohort studies have reported conflicting findings on the association between dietary sodium intake and CVD ([@B9]; [@B36], [@B35]). Moreover, emerging studies suggested that extreme strict sodium control may be harmful rather than beneficial as previously recommended in CKD patients ([@B14]). Debates about optimal sodium intake in the general population are still ongoing ([@B32], [@B33]). During the 2017 KDIGO controversies conference, stakeholders questioned whether a level 1C recommendation of sodium restriction (\<2 g of sodium per day) was too strong based on the current evidence ([@B8]).

Given that few randomized controlled trials have been conducted to infer causality between salt intake and kidney outcomes, the genetic variants associated with potential risk factors offer the opportunity to test the causal effect of salt intake on CKD through Mendelian randomization (MR) ([@B40]; [@B50]). In essence, MR exploits the random allocation of genetic variants at conception and therefore is less susceptible to confounding compared to traditional observational studies. Furthermore, MR studies give the effects of lifetime exposures and so could evaluate the long-term effect. Recently, Zanetti et al. performed genome-wide association studies (GWASs) of urinary electrolyte excretion, including the urinary sodium/urinary creatinine (UNa/UCr) ratio, in up to 327,616 unrelated individuals of European ancestry from the UK Biobank ([@B49]). Since spot urine samples were commonly used to estimate 24-h sodium excretion as a surrogate for salt intake ([@B24]; [@B32], [@B33]), we aimed to assess the causal effect of salt intake, using UNa/UCr as proxy, on kidney function in Europeans using MR ([@B19]).

Materials and Methods {#S2}
=====================

Genetic Predictors of Urinary Sodium Excretion {#S2.SS1}
----------------------------------------------

In a recent genetic study of urinary sodium excretion normalized for creatinine (calculated as UNa/UCr), 327,616 eligible individuals from the UK Biobank were included and two-thirds of the sample (*n* = 218,450) were randomly selected for discovery GWAS ([@B49]). Association analysis was conducted using linear regression of UNa/UCr levels on imputed genotypes, assuming an additive model between phenotype and genotype dosages. The model was adjusted for age, sex, batch, and the first 10 genotype principal components. Six conditional distinguished genetic variants strongly associated with UNa/UCr (*P* \< 5 × 10^--8^) were selected as candidate instruments ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

Genetic Associations of Kidney Function Phenotypes {#S2.SS2}
--------------------------------------------------

Creatinine-based estimated glomerular filtration rate (eGFRcrea) and CKD (eGFRcrea \< 60 ml/min/1.73 m^2^, binary phenotype) were used as proxies for kidney function phenotypes. eGFRcrea was estimated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula ([@B27]). It was estimated as 141 × min(Scr/κ, 1)^α^ × max(Scr/κ, 1)^--1.209^ × 0.993^*Age*^ × 1.018 (if female)\_1.159 (if black), where Scr is the serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. GWAS summary statistics of eGFRcrea (*N* = 567,460) and CKD (*N* cases = 41,395; *N* controls = 439,303; *N* total = 480,698) from the CKDGen consortium were utilized ([@B47]). The GWASs were imputed using the 1000 Genomes phase 1 v3 training set with 38 million variants. Genetic associations were adjusted for study specific covariates such as age and sex, and the first 10 principal components were also used as covariates in the association model of the GWAS to control for the population stratification.

Mendelian Randomization {#S2.SS3}
-----------------------

MR is an instrumental variable method that uses genetic variants as instruments to test the casual relationships between an exposure (e.g., UNa/UCr) and an outcome (e.g., eGFRcrea/CKD). The causal association between the exposure and the outcome will be valid when the three core MR assumptions were satisfied ([Figure 1](#F1){ref-type="fig"}). In our initial MR analysis, UNa/UCr was treated as exposure and eGFRcrea/CKD as outcomes, using the UNa/UCr-associated single-nucleotide polymorphisms (SNPs) as instrument variables. We used the random-effect inverse variance weighted (IVW) method ([@B7]) to estimate the MR effect, which pools the individual SNP Wald estimator ([@B23]) by meta-analysis. The Cochrane's Q and Rocker's Q statistics were used to estimate the level of heterogeneity of the IVW and MR-Egger regression separately, in which the degree of freedom for Cochrane's Q is the number of SNPs minus one and that for Rocker's Q is the number of SNPs minus two.

![The diagram and three key assumptions of Mendelian randomization.](fbioe-08-00662-g001){#F1}

We further tested the MR assumptions using the following sensitivity analyses. MR-Egger regression ([@B4]) was used to test pleiotropic effects of the instruments on outcomes, independent of exposures. The MR-Egger regression intercept was recorded as an indicator of pleiotropy. We also performed MR analyses using the weighted median MR approach ([@B5]) and the mode estimate MR approach ([@B16]), which provides consistent causal estimates of the exposure on the outcome even when up to 50% (or even 0%) of the information contributing to the analysis comes from genetic variants that exhibit pleiotropy. If all approaches (i.e., IVW MR, MR-Egger regression, weighted median MR, and mode estimate MR) provide consistent causal estimates of UNa/UCr on eGFRcrea/CKD, the MR findings will be more robust. To exclude the influence of pleiotropy instruments on the MR estimates, we applied MR-PRESSO ([@B45]) as another sensitivity analysis, which attempts to reduce heterogeneity in the estimate of the causal effect by removing SNPs that contribute to the heterogeneity disproportionately more than expected.

Directionality Analysis {#S2.SS4}
-----------------------

### Steiger Filtering {#S2.SS4.SSS1}

When applying MR, we assume that SNPs used as proxies of UNa/UCr exert their primary association on UNa/UCr and that any correlation with eGFRcrea or CKD is a consequence of a causal effect of UNa/UCr on eGFRcrea or CKD. We therefore performed Steiger filtering analyses ([@B19]), implemented in the TwoSampleMR R package, to test the directionality of UNa/UCr instruments. The underline concept of Steiger filtering is a simple inequality. Given that phenotype A causes phenotype B, then we would expect that
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since *cor*(*g~*i*~, B*)^2^ = *cor*(*A*, *B*)^2^ ^∗^ *cor*(*g*~*i*~, *A*)^2^, where "*cor*" denotes correlation, and the vector *g* contains a set of SNPs that influence phenotype A. For any instrument that had a *cor*(*g*~*i*~, *A*)^2^ \< *cor*(*g*~*i*~, *B*)^2^, they showed evidence of primarily affecting eGFR rather than UNa/UCr. We thus removed these UNa/UCr instruments and performed the MR analyses using the remaining instruments.

### Bidirectional MR {#S2.SS4.SSS2}

To investigate the potential reverse causality of eGFRcrea/CKD on UNa/UCr, we conducted a bidirectional MR. We first found 256 conditional independent variants associated with eGFRcrea and 23 independent variants associated with CKD ([Supplementary Table S2](#TS1){ref-type="supplementary-material"}) using the linkage disequilibrium clumping (*r*^2^ \< 0.001) function implemented in the TwoSampleMR R package. We then used eGFRcrea or CKD as exposures and UNa/UCr as the outcome for the bidirectional MR. Considering that eGFRcrea has GFR and marker determinants, we further performed sensitivity analyses by using blood urea nitrogen (BUN) GWAS ([@B47]) to prioritize eGFRcrea-associated SNPs as exposures. More specifically, we required the eGFRcrea SNPs be associated with BUN in the opposite direction (since higher GFR would lead to lower BUN) and the eGFRcrea SNPs be associated with BUN with a Bonferroni-corrected significance. In addition, cystatin C, an alternative biomarker of kidney function, was measured in a subset of European ancestry participants from the CKDGen consortium (*N* = 32,861) ([@B28]). Cystatin C-based eGFR (eGFRcys) could be estimated as 76.7 × serum cystatin C ([@B26]). To further exclude the possible bias caused by creatinine, we extracted five SNPs that robustly associated with eGFRcys ([@B28]) and used them as instruments for a sensitivity MR analysis against UNa/UCr.

MR and Visualization Software {#S2.SS5}
-----------------------------

The MR results were presented as scatter plots and forest plots using a code derived from the ggplot2 package in R^[1](#footnote1){ref-type="fn"}^. All MR and sensitivity analyses were conducted using the TwoSampleMR R package^[2](#footnote2){ref-type="fn"}^ ([@B19]). MR-PRESSO test was conducted by using the MR-PRESSO R package^[3](#footnote3){ref-type="fn"}^. The number of distributions was set to 10,000, and the threshold was set to 0.05.

24-h Urinary Sodium Estimation {#S2.SS6}
------------------------------

The exact intake of sodium cannot be measured precisely but can be estimated from 24-h sodium excretion ([@B20]). Thus, to estimate the sodium intake, we used the INTERSALT (International Cooperative Study on Salt, Other Factors, and Blood Pressure) equation ([@B6]), developed in a sample of 3,093 European-descent individuals aged 20--59 years, to estimate the 24-h urine sodium excretion based on the reported spot urine measurements. The equation was described as follows.

For men:

24-h sodium excretion (mg) = 23 × {25.46 + \[0.46 × spot urine sodium (mmol/L)\] − \[2.75 × spot urine creatinine (mmol/L)\] − \[0.13 × spot urine potassium (mmol/L)\] + \[4.10 × body mass index (kg/m^2^)\] + \[0.26 × age (years)\]}.

For women:

24-h sodium excretion (mg) = 23 × {5.07 + \[0.34 × spot urine sodium (mmol/L)\] − \[2.16 × spot urine creatinine (mmol/L)\] − \[0.09 × spot urine potassium (mmol/L)\] + \[2.39 × body mass index (kg/m^2^)\] + \[2.35 × age (years)\] − \[0.03 × age^2^ (years)\]}.

Results {#S3}
=======

Effect of UNa/UCr on eGFRcrea and CKD {#S3.SS1}
-------------------------------------

[Figure 2](#F2){ref-type="fig"} showed the MR results of UNa/UCr on eGFRcrea and CKD. For eGFRcrea, the IVW MR suggested that UNa/UCr was positively associated with eGFRcrea \[β = 0.14, unit change in log ml/min/1.73 m^2^ per UNa/UCr ratio; 95% confidence interval (CI) = 0.07 -- 0.20, *P* = 2.15 × 10^--5^, [Figure 2A](#F2){ref-type="fig"}\]. Similarly, the IVW MR suggested that increased UNa/UCr was associated with reduced CKD risk \[odds ratio (OR) = 0.24, 95% CI = 0.14 to 0.41, *P* = 1.20 × 10^--7^, [Figure 2B](#F2){ref-type="fig"}\]. The SNP MR results presented by the forest plots suggested that the causal effects of UNa/UCr on eGFRcrea/CKD were similar across instruments, and the observed MR findings were not massively influenced by any single instrument ([Figures 2A,B](#F2){ref-type="fig"}). [Figures 2C,D](#F2){ref-type="fig"} showed scatter plots of the SNP-outcome associations against the SNP-UNa/UCr associations, allowing visualization of the causal effect for individual SNP on eGFRcrea/CKD.

![Forest plot and scatter plot for causal effects of urinary sodium/creatinine ratio on eGFRcrea and CKD. The forest plot shows the Wald ratio estimate of each UNa/UCr instrument on eGFRcrea **(A)** or CKD **(B)**. The scatter plots display the causal estimates of UNa/UCr (*x*-axis) against eGFRcrea **(C)** or CKD **(D)**. Each point refers to one UNa/UCr instrument. The slopes of the lines represent the causal estimates of UNa/UCr on CKD or eGFRcrea using inverse variance weighted, MR-Egger regression, weighted median, and mode estimate approaches. The *y*-intercept of the MR-Egger regression line is an estimate of the degree of horizontal pleiotropy in the dataset. Notation: CKD, chronic kidney disease; eGFRcrea, creatinine-based estimated glomerular filtration rate; IVW, inverse variance weighted; UNa/UCr, urinary sodium/urinary creatinine ratio.](fbioe-08-00662-g002){#F2}

Cochrane's Q test (*P* = 7.03 × 10^--7^ and 5.83 × 10^--3^ for eGFRcrea and CKD as outcomes, respectively) and Rocker's *Q*-test (*P* = 6.72 × 10^--7^ and 2.29 × 10^--3^ for eGFRcrea and CKD as outcomes, respectively) suggested the presence of considerable heterogeneity in the analysis. However, the MR-Egger intercept suggested little evidence of horizontal pleiotropy (*P* = 0.65 and 0.98 for eGFRcrea and CKD as outcome, respectively) ([Supplementary Table S3](#TS1){ref-type="supplementary-material"}).

Sensitivity Analyses {#S3.SS2}
--------------------

[Table 1](#T1){ref-type="table"} showed the MR estimates of UNa/UCr on eGFRcrea and CKD using other sensitivity MR approaches, which are more robust to pleiotropy. For eGFRcrea, the IVW MR result was consistent with the casual estimates using MR-Egger regression (β = 0.32, 95% CI = 0.06 -- 0.58, *P* = 1.66 × 10^--2^), weighted median MR (β = 0.07, 95% CI = 0.04 -- 0.11, *P* = 8.68 × 10^--6^), and mode-based estimate MR approaches (β = 0.05, 95% CI = 0.02 -- 0.09, *P* = 1.82 × 10^--2^), which increased the robustness of the MR results. For CKD, the IVW MR estimates were concordant in direction with the MR estimates using MR-Egger (OR = 0.32, 95% CI = 0.02 -- 4.97, *P* = 0.46), weighted median MR (OR = 0.23, 95% CI = 0.14 -- 0.40, *P* = 1.40 × 10^--7^), and mode-based MR approaches (OR = 0.20, 95% CI = 0.10 -- 0.41, *P* = 7.55 × 10^--3^). In consistent with these results, we also observed positive causal effect of UNa/UCr on eGFRcys ([Supplementary Table S4](#TS1){ref-type="supplementary-material"}). Given that some of the instruments might be influenced by horizontal pleiotropy, we applied the MR-PRESSO outlier test and identified three UNa/UCr instruments as potential outliers. The MR estimate after removing the outliers identified by MR-PRESSO suggested a consistent positive effect of UNa/UCr on eGFRcrea (MR-PRESSO estimate: β = 0.129, 95% CI = 0.076 -- 0.182, *P* = 4.14 × 10^--2^; [Supplementary Table S5](#TS1){ref-type="supplementary-material"}).

###### 

Mendelian randomization analyses of causal effects of urinary sodium/urinary creatinine ratio on eGFRcrea and CKD.

  **Trait**   **Number of SNPs**   **Methods**          **Estimator (95% CI)**     ***P***
  ----------- -------------------- -------------------- -------------------------- ----------------
  eGFRcrea    6                    MR IVW               β = 0.14 (0.07 -- 0.20)    2.15 × 10^--5^
              6                    MR-egger             β = 0.32 (0.06 -- 0.58)    1.66 × 10^--2^
              6                    MR-weighted median   β = 0.07 (0.04 -- 0.11)    8.68 × 10^--6^
              6                    MR-weighted mode     β = 0.05 (0.02 -- 0.09)    1.82 × 10^--2^
  CKD         6                    MR IVW               OR = 0.24 (0.14 -- 0.41)   1.20 × 10^--7^
              6                    MR-egger             OR = 0.32 (0.02 -- 4.97)   0.46
              6                    MR-weighted median   OR = 0.23 (0.14 -- 0.40)   1.40 × 10^--7^
              6                    MR-weighted mode     OR = 0.20 (0.10 -- 0.41)   7.55 × 10^--3^

The confidence interval of MR-Egger estimates was wider compared to that of other methods because the statistical power of the MR-Egger was, in general, lower than that of MR IVW and weighted median. CKD, chronic kidney disease; eGFRcrea, creatinine-based estimated glomerular filtration rate; MR, Mendelian randomization; IVW, inverse variance weighted, OR, odds ratio; SNP, single-nucleotide polymorphism.

Directionality Tests {#S3.SS3}
--------------------

The Steiger filtering results suggested that all instruments were primarily influencing UNa/UCr than affecting eGFRcrea as a consequence ([Supplementary Table S6](#TS1){ref-type="supplementary-material"}), which further confirmed the robustness of the instruments. As shown in [Figure 3](#F3){ref-type="fig"}, bidirectional MR using CKD, eGFRcrea, eGFRcrea (BUN associated), and eGFRcys as exposures and UNa/UCr as an outcome suggested inconsistent evidence of causal effect of kidney function on UNa/UCr ([Supplementary Table S7](#TS1){ref-type="supplementary-material"}).

![Mendelian randomization analyses of causal effects of eGFR/CKD on urinary sodium/creatinine ratio. BUN, blood urea nitrogen; eGFRcrea, creatinine-based estimated glomerular filtration rate; eGFRcrea (BUN associated), the eGFRcrea-associated SNPs were required to be associated with BUN in opposite direction (since higher GFR would lead to lower BUN) and to be associated with BUN with a Bonferroni-corrected significance; eGFRcys, cystatin C-based estimated glomerular filtration rate.](fbioe-08-00662-g003){#F3}

Sodium Intake Estimation {#S3.SS4}
------------------------

The mean age, body mass index, UNa/UCr, and urinary potassium/UCr were 56.88, 27.39, 10.60, and 8.48, respectively, in the discovery population and were 56.87, 27.42, 10.62, and 8.44, respectively, in the replication population ([@B49]). Using these baseline characteristics, the average 24-h sodium excretion was estimated to be approximately 2.6 g per day for women and 3.7 g per day for men, well above the recommended restriction of \<2 g per day of sodium intake ([Supplementary Table S8](#TS1){ref-type="supplementary-material"}).

Discussion {#S4}
==========

Sodium intake was reported to be one of the most important modifiable risk factors influencing blood pressure and proteinuria, yet its impact on renal outcomes is uncertain. Using a two-sample MR approach, we tested the causal effect of sodium intake, using estimated 24-h sodium excretion from a spot UNa/UCr ratio as a surrogate, on kidney function. We found that each unit increase in the UNa/UCr ratio was associated with a 0.14 unit increase in log(eGFRcrea) and with reduced CKD risk (OR = 0.24). These MR findings were confirmed by MR-Egger regression, weighted median MR, and mode estimate MR, which suggested less evidence of existence of horizontal pleiotropy. Steiger filtering suggested less evidence of reverse causality of CKD on UNa/UCr. Cochrane's *Q* and Rocker's *Q* statistics suggested the presence of considerable heterogeneity in the analysis. However, the MR-Egger intercept suggested little evidence of horizontal pleiotropy. Consistent positive causal effect of UNa/UCr on eGFRcys was also detected. Bidirectional MR using CKD, eGFRcrea, eGFRcrea (BUN associated), and eGFRcys as exposures showed weak evidence supporting a causal relationship for kidney function on UNa/UCr. The average 24-h sodium excretion was estimated to be approximately 2.6 g per day for women and 3.7 g per day for men, well above the recommendation of \<2 g per day of sodium intake in the KDIGO guideline. Our results support that reducing dietary sodium intake under 2 g per day in CKD might be overcontrolled and may not have a beneficial effect on reducing CKD risk as expected.

Sodium intake was regarded as one of the important modifiable risk factors for CKD progression. The exact intake of sodium cannot be measured precisely but can be estimated from dietary questionnaires or 24-h sodium excretion ([@B20]). However, questionnaires are usually self-reported and require calculations by a nutritionist and thus may be imperfect measures of sodium intake ([@B25]), while the 24-h urine sample collection is limited to poor compliance and cost. Thus, studies usually used spot urine samples to estimate 24-h sodium excretion as a surrogate for sodium intake ([@B32], [@B33]). To compensate for variation in urine concentration, urinary sodium corrected by urinary creatinine could be used for assessing sodium excretion in urine over 24-h ([@B24]). Using these methods, previous observational studies have provided inconsistent results on the effects of dietary sodium intake on the risk of CKD. Some studies suggested that urinary sodium excretion was associated with increased risk of CKD progression and incidence of end-stage renal disease (ESRD) ([@B29]; [@B44]; [@B37]; [@B30]), while others indicated that urinary sodium excretion was not associated with the risk of CKD or renal failure ([@B12]; [@B14]; [@B41]), even protected against cumulative incidence of ESRD ([@B13]; [@B43]). The inconsistent results may be due to the fact that these studies were observational studies that cannot make causal inference.

Until now, previous trials mainly focused on the blood pressure lowering effect of sodium control, but there are limited evidence detailing the effects of sodium restriction in CKD patients. For example, the Holland Nephrology Study (HON-EST) suggested that the addition of a low-sodium diet further reduced 11 mmHg systolic blood pressure in patients with treatment with an angiotensin converting enzyme inhibitor ([@B39]). Vogt found reductions of 6/3 mmHg systolic blood pressure/diastolic blood pressure in proteinuric patients without diabetes who received a low-sodium diet ([@B46]). Two more recent studies provided new clinical trial data from randomized, double-blind, crossover trials in patients with stages 3 and 4 CKD ([@B31]; [@B38]). They found that salt restriction resulted in statistically significant reductions of blood pressure and albuminuria. However, although salt intake has been extensively suggested to be associated with blood pressure, high sodium intake-related increase in blood pressure might not entirely explain the elevated risk of CKD progression and renal failure in patients with CKD. What's more, it must be noted that it is unable to compare the clinical outcomes among patients with urinary sodium excretion \<2 g per day recommended in clinical practice guideline, which appears difficult to achieve. Results from most trials showed that only high urinary sodium excretion (approximately 150--200 mmol or 3.5--4.5 g sodium per day), well above the recommended limit (2 g sodium per day), was associated with increased risk of CKD progression or all-cause mortality ([@B34]; [@B22]; [@B31]; [@B18]). Thus, using these data is hard to assess whether sodium restriction \<2 g per day is suggestively hazardous or intuitively advantageous ([@B3]).

In the current study, we used the two-sample MR approach to test the causal effect of UNa/UCr on kidney outcomes. We further estimated the 24-h urine sodium excretion to estimate sodium intake using the previously published sodium excretion estimating equation based on spot urine measurements, which was developed and validated in European populations ([@B6]). We found that UNa/UCr showed causal effect on higher eGFRcrea and lower CKD risk, while weak evidence of causal association between kidney function and UNa/UCr was observed. Using baseline characteristics of the UK Biobank participants, the average 24-h sodium excretion was estimated to be approximately 2.6 g per day for women and 3.7 g per day for men. Previous studies suggested that this estimation equation might underestimate the urinary sodium excretion ([@B2]). Although potential bias exists in estimating 24-h sodium excretion using casual urinary test ([@B11]), our results support that reducing dietary sodium intake under 2 g per day in CKD was too restrictive and might not be beneficial to reduce the risk of CKD development or progression as expected.

Several limitations should be mentioned in this study. First, 24-h urine collection was estimated rather than performed in the study population; target levels of UNa/UCr for protecting effects were not evaluated. In the future, additional large randomized controlled trials are required to determine the optimal target sodium intake. Second, we currently have limited access to the individual level genotype and phenotype data to perform further stratification of groups by instruments or outcomes and distributions. This type of analysis is needed to determine the optimal target of sodium intake in CKD in the future. Third, this study is limited to the only six instruments of UNa/UCr, even though they were derived from the well-powered and most recent UNa/UCr GWAS. Most of the current MR sensitivity analysis methods such as MR-Egger regression and weighted median need a large number of independent instrumental SNPs in order to test for pleiotropy. Thus, the MR results presented in this paper should be taken with caution. Fourth, the MR Steiger filtering approach has limitations, i.e., some levels of horizontal pleiotropy, where the SNP influences the outcome through some pathways other than the exposure, could induce problems because this is a means by which the instrument is invalid. Besides, some levels of unmeasured confounding between the exposure and the outcome could lead to inference of the wrong causal direction. We therefore applied a well-validated method MR-PRESSO. After controlling for pleiotropy instruments, our finding was still consistent. Finally, as in most epidemiological studies, MR assumes a linear relation between UNa/UCr and eGFR/CKD, which might not invariably be the case.

In conclusion, we found that a higher UNa/UCr ratio, which reflects proportionally higher salt intake, showed causal effects on higher eGFR and lower CKD risk. Further long-term studies to determine optimal target of sodium intake in CKD are required.
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